Skip to main content

Table 1 Demographic Characteristicsa

From: Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study

  

Previous Treatment in Main Study

 

Total Group

Ovaleap®

Gonal-f®

Cycle 2

N = 147

N = 80

N = 67

 Age, years

   

  Mean (SD)

31.6 (3.3)

31.4 (3.4)

31.9 (3.0)

 Age, n (%)

   

   < 30 years

37 (25.2)

23 (28.8)

14 (20.9)

  30 to 34 years

77 (52.4)

42 (52.5)

35 (52.2)

   > 34 years

33 (22.4)

15 (18.8)

18 (26.9)

 Weight, kg

   

  Mean (SD)

63.2 (9.4)

63.1 (9.8)

63.4 (8.8)

 BMI, kg/m2

   

  Mean (SD)

22.7 (2.8)

22.7 (2.8)

22.6 (2.8)

 Smoker, n (%)

20 (13.6)

13 (16.3)

7 (10.4)

 Alcohol consumption, n (%)

25 (17.0)

18 (22.5)

7 (10.4)

Cycle 3

N = 61

N = 34

N = 27

 Age, years

   

  Mean (SD)

31.6 (3.2)

31.1 (3.5)

32.3 (2.8)

 Age, n (%)

   

   < 30 years

13 (21.3)

10 (29.4)

3 (11.1)

  30 to 34 years

34 (55.7)

19 (55.9)

15 (55.6)

   > 34 years

14 (23.0)

5 (14.7)

9 (33.3)

 Weight, kg

   

  Mean (SD)

63.5 (8.9)

62.5 (8.2)

64.7 (9.7)

 BMI, kg/m2

   

  Mean (SD)

23.0 (2.9)

22.8 (2.8)

23.3 (3.1)

 Smoker, n (%)

11 (18.0)

7 (20.6)

4 (14.8)

 Alcohol consumption, n (%)

13 (21.3)

8 (23.5)

5 (18.5)

  1. BMI body mass index; SD standard deviation
  2. aReasons for and duration of infertility were comparable between the Ovaleap® and Gonal-f® groups in the Main Study [9]